Seminar Title: Building a Continuous Crystallization, Isolation, and Drying Capability at Pfizer
PBB 131
Wednesday November 6th, 2024, from 3:30 pm – 4:30 pm
Dr. Kevin Girard began an industrial career as a chemical engineer with Bristol-Myers Squibb (BMS), where he studied the filtration and drying of active pharmaceutical ingredients (API’s). This assignment put Kevin at the interface between API and drug and allowed him to be one of the key players in the early adoption of Process Analytical Technology (PAT) at BMS. In 2006, Dr. Girard joined Pfizer, where he has spent the last 16 years in the Pfizer Crystallization Technology Lab (CTL). Kevin has lead the development and implementation of new and emerging crystallization technology and has applied these tools to develop crystallization processes for over 31 different medicines that are on the market or in development. To date, Kevin’s processes have been used in the manufacture of Reyataz™, Tequin™, Baraclude™, Vyndaquel™, Bosulif™, Vizimpro™, and Abrocitinib™. Dr. Girard has over 30 peer-reviewed publications and three international patents. When he is not busy crystallizing the next wave of therapies, Kevin enjoys aviation (instrument rated pilot), golf, kiteboarding, coaching/watching/playing soccer, and spending time with his three children in CT.
Education & Training
University of Pennsylvania
Rensselaer Polytechnic Institute
For more information, contact: Reena Bokria at rjb07003@uconn.edu